Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells-Reference-Cited by-同舟云学术

Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells

Published:2017-05-04 Issue:5 Volume:6 Page:e1312239
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Thiel Uwe¹,Schober Sebastian J.¹,Einspieler Ingo²,Kirschner Andreas¹,Thiede Melanie¹,Schirmer David¹,Gall Katja¹,Blaeschke Franziska¹,Schmidt Oxana¹,Jabar Susanne³,Ranft Andreas³^ORCID,Alba Rubío Rebeca⁴⁵,Dirksen Uta³,Grunewald Thomas G. P.⁴⁵⁶,Sorensen Poul H.¹⁷⁸,Richter Günther H. S.¹,von Lüttichau Irene Teichert¹,Busch Dirk H.⁹⁸,Burdach Stefan E. G.¹⁶

Affiliation:

1. Department of Pediatrics and Children‘s Cancer Research Center, Kinderklinik München Schwabing, Technische Universität München, Munich, Germany

2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

3. Department of Pediatric Hematology and Oncology, Westfälische Wilhelms Universität, Münster, Germany

4. Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU, Munich

5. German Cancer Research Center (DKFZ), Heidelberg, Germany

6. CCC München Comprehensive Cancer Center and German Translational Cancer Research Consortium (DKTK), Partner Site Munich, Munich, Germany

7. Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada

8. Institute for Advanced Study, Technische Universität München, Munich, Germany

9. Institute of Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1312239

Reference30 articles.

1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

2. The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma

3. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG

4. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow

5. Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model;Frontiers in Immunology;2024-01-22

2. Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field;Cancers;2023-08-16

3. Targeted Therapy for EWS-FLI1 in Ewing Sarcoma;Cancers;2023-08-09

4. Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype;Biomedicines;2023-03-13

5. Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing;Blood Advances;2023-03-03